.png)
Oncology Updates - Key Oncology News
- Oncofocus Team
- 2 hours ago
- 2 min read
May 1st Week, 2026
Regulatory Events
🎯 Pierre Fabre Laboratories aligned with the US FDA for resubmission of the BLA for tabelecleucel (allogeneic T‑cell therapy) for R/R EBV+ post‑transplant lymphoproliferative disease who have received at least one prior therapy including an anti-CD20 containing regimen (Ref 1)
❓ How is tabelecleucel positioned in the current Lymphoma market landscape?
🎯 Nuvation Bio’s supplemental NDA with updated data for taletrectinib (IBTROZI®; TKI) in both TKI-naïve and TKI-pretreated advanced ROS1+ NSCLC was accepted by the US FDA, with a target action date of January 4, 2027 (Ref 2)
❓ How will an expanded label impact the market position of taletrectinib?
🎯 A protocol amendment to the ongoing pivotal Phase 3 NANORAY-312 study of Johnson & Johnson Innovative Medicine and Nanobiotix’s JNJ-1900/NBTXR3 (Radiotherapy-activated hafnium oxide nanoparticles) in locally advanced HNSCC was accepted by the US FDA; the amendment eliminates the previously planned interim analysis and modifies the final analysis to include fewer events than originally planned and to be conducted sooner (Ref 3)
❓ What is the addressable market for JNJ-1900/NBTXR3 in HNSCC?
Special Designations
⭐ The US FDA awarded a Commissioner’s National Priority Voucher (CNPV) to Partner Therapeutics’ zenocutuzumab (BIZENGRI®; HER2/HER3 BsAb) for the treatment of adults with advanced, unresectable or metastatic cholangiocarcinoma with NRG1 fusion, with disease progression on or after prior systemic therapy (Ref 4)
❓ Who are the key competitors in the cholangiocarcinoma development landscape?
⭐ The US FDA granted a Fast Track designation to Diakonos Oncology’s DOC1021 (patient-derived, double-loaded dendritic cell therapy) for the treatment of unresectable or metastatic cutaneous melanoma (Ref 5)
❓ What are the current clinical benchmarks for cutaneous melanoma?
Deals and Collaborations
🤝 Halozyme, Inc. entered a global collaboration and license agreement with GSK to use its ENHANZE® drug delivery technology for subcutaneous administration of multiple oncology targets, including antibody-drug conjugates (ADCs). GSK also has options for additional future targets. (Ref 6)
❓ How is this collaboration expected to benefit GSK’s pipeline?
To know answers to these questions and for additional insights, write to us at support@oncofocus.com.
🌐 References:
Comments